Change Country
Welcome to Norway
Please read the important information below before continuing to our website

Please read the important information below before continuing to our website.  

By clicking on your client type to enter the website, you are confirming that you have read and understood the important information that is contained below, and you accept the terms of the Privacy and Cookies policy.

THIS WEBSITE IS AIMED AT PROFESSIONAL CLIENTS IN NORWAY

This website is published by Lyxor International Asset Management (LIAM), a French asset management company approved by the AMF (17 place de la Bourse 75082 Paris Cedex 02) under the UCITS (2009/65/EC) and AIFM (2011/31/EU) directives.

The website is hosted by on Microsoft Azure servers.

This website is subject to French and Norwegian law.

 

A professional client is a client that is either a per se professional client or an elective professional client (Note article 4 (1) 12 of Mifid )

Marketing Restrictions and Implications

 

Lyxor UCITS compliant Exchange Traded Funds (Lyxor UCITS ETFs) referred to on this website are open ended mutual investment funds (i) established under the French law and approved by the Autorité des Marchés Financiers (the French Financial Markets Authority), or (ii) established under the Luxembourg law and approved by the Commission de Surveillance du Secteur Financier (the Luxembourg Financial Supervisory Committee). Most, , of the protections provided by the Danish regulatory system generally and for funds authorised in Denmark do not apply to these exchange traded funds (ETFs).

 

This website is exclusively intended for persons who are not "US persons", as such term is defined in Regulation S or the US Securities Act 1933, as amended, and who are not physically present in the US. This website does not constitute an offer or an invitation to purchase any securities in the United States or in any other jurisdiction in which such offer or invitation is not authorised or to any person to whom it is unlawful to make such offer or solicitation. Potential users of this website are requested to inform themselves about and to observe any such restrictions.

 

Index Replication Process

 

Lyxor UCITS ETFs follow both physical and synthetic index replication process.

 

However, most Lyxor UCITS ETFs follow synthetic replication process. This consists of entering into a derivative transaction (a ‘Performance Swap’, as defined below) with a counterparty that provides complete and effective exposure to its benchmark index. Lyxor has adopted this methodology in order to minimise tracking error, optimise transaction costs and reduce operational risks.

 

A Performance Swap is a contractual agreement which is negotiated over-the-counter (OTC) between two parties: the Lyxor UCITS ETF and its counterparty. From a risk perspective, each Performance Swap ranks equally with other senior unsecured obligations of the counterparty, such as common bonds (i.e., same rights to payments). In the Performance Swap, the counterparty of the Lyxor UCITS ETF commits to pay the Lyxor UCITS ETF a variable return based on a pre-determined benchmark index, instead of a fixed stream of income (as in bonds). At the same time, the counterparty will receive from the Lyxor UCITS ETF the performance and any related revenues generated by the basket's assets (excluding the value of the Performance Swap) held by the Lyxor UCITS ETF. Information provided on individual ETFs includes data on the basket relating to the ETF and the percentage value of the basket represented by each asset. The information is relevant to the closing values on the date given. 

 

Investment Risks

 

The Lyxor UCITS ETFs described on this website are not suitable for everyone. Investors' capital is at risk. Investors should not deal in this product unless they understand, having obtained independent professional advice where necessary, its nature, terms and conditions, and the extent of their exposure to risk. The value of the product can go down as well as up and can be subject to volatility due to factors such as price changes in the underlying instrument and interest rates. If a fund is quoted in a different currency to the index, currency risks exist.

 

Prior to any investment in any Lyxor UCITS ETF, you should make your own appraisal of the risks from a financial, legal and tax perspective, without relying exclusively on the information provided by us. We recommend that you consult your own independent professional advisors (including legal, tax, financial or accounting advisors, as appropriate).

 

Specific Risks

 

·         Capital at Risk. ETFs are tracking instruments: Their risk profile is similar to a direct investment in the Benchmark Index. Investors’ capital is fully at risk and investors may not get back the amount originally invested. Investments are not covered by the provisions of the Financial Services Compensation Scheme (“FSCS”), or any similar scheme.

·         Counterparty Risk. Investors may be exposed to risks resulting from the use of an OTC Swap with Societe Generale. Physical ETFs may have Counterparty Risk resulting from the use of a Securities Lending Programme.

·         Currency Risk. ETFs may be exposed to currency risk if the ETF or Benchmark Index holdings are denominated in a currency different to that of the Benchmark Index they are tracking. This means that exchange rate fluctuations could have a negative or positive effect on returns.

·         Replication Risk. ETFs are designed to replicate the performance of the Benchmark Index. Unexpected events relating to the constituents of the Benchmark Index may impact the Index provider’s ability to calculate the Benchmark Index, which may affect the ETF’s ability to replicate the Benchmark Index efficiently. This may create Tracking Error in the ETF.

·         Underlying Risk. The Benchmark Index of a Lyxor ETF may be complex and volatile. When investing in commodities, the Benchmark Index is calculated with reference to commodity futures contracts which can expose investors to risks related to the cost of carry and transportation. ETFs exposed to Emerging Markets carry a greater risk of potential loss than investment in Developed Markets as they are exposed to a wide range of unpredictable Emerging Market risks.

·         Liquidity Risk. On-exchange liquidity may be limited as a result of a suspension in the underlying market represented by the Benchmark Index tracked by the ETF; a failure in the systems of one of the relevant stock exchanges, Societe Generale or other Market Maker systems; or an abnormal trading situation or event. 

 

The securities can be neither offered in nor transferred to the United States.

 

Tax

 

Any statement in relation to tax, where made, is generic and non-exhaustive and is based on our understanding of the laws and practice in force as of the date of this document and is subject to any changes in law and practice and the interpretation and application thereof, which changes could be made with retroactive effect. Any such statement must not be construed as tax advice and must not be relied upon. The tax treatment of investments will, inter alia, depend on an individual’s circumstances. Investors must consult with an appropriate professional tax adviser to ascertain for themselves the taxation consequences of acquiring, holding and/or disposing of any investments mentioned on this website. 

Further information on the risk factors are available in the [Risk Warning – link to risk page] section of the website.

 

Any fund prospectus and supplements are available at www.lyxoretf.dk. Information given about the past performance of the funds is no guarantee of future performance. No investment decision should be taken without reading the fund prospectus and any fund supplement of the fund concerned.

 

Although the content of the website is based upon information that LIAM consider reliable or comes from sources that LIAM consider reliable, LIAM have not verified such information. Lyxor make no representation or warranty as to the accuracy, completeness or adequacy of any information.  Any reproduction, disclosure or dissemination of the materials available on the website is prohibited.

 

Cookies

This website uses cookies to make the website work or improve your user experience. Cookies are small text files that are saved on your computer or device, which are used for several purposes such as detecting preferences and improving site navigation. By continuing to use this website you consent for cookies to be used. For more details, including how to amend your preferences, please read our [Cookies Policy] link to privacy & cookie page.

By clicking on your client type to enter the website, you shall be deemed to have represented to us that you are not a U.S. person and that you are not located in the United States of America, its territories and possessions, and any State of the United States of America and that you are authorised to receive the information to and on this website.

August, 2015

 

 

 

I CONFIRM THAT I HAVE READ AND UNDERSTOOD THE IMPORTANT INFORMATION THAT IS CONTAINED ABOVE AND ACCEPT THE TERMS OF THE PRIVACY AND COOKIES POLICY.

By continuing to browse the site, you are agree on the use of cookies to track the number of visits.To know more about cookies policy:Click here
26 Feb 2020

The coronavirus outbreak highlights a better way to invest in China

The outbreak and spread of a coronavirus from the central Chinese city of Wuhan has triggered a risk-off global mood. Aside from the human cost of the illness, many of the world’s biggest companies base parts of their supply chain in China, and some are warning of decreased output and revenue due to supply-chain disruption. Markets shuddered in early February but are proving resilient as the month goes on. History suggests that any further market falls may present an opportunity for long-term investors.

What’s happened?

  • Global markets have had a turbulent few weeks as investors digested the impact of the Wuhan coronavirus, dubbed Covid-19. Globally, there have been 73,332 cases confirmed of this variant of coronavirus, and more than 2,000 deaths.  The human impact of the coronavirus has been largely confined to the Asia-Pacific region, but the commercial ramifications are already being felt across the globe, particularly in the tech and automotive sectors, as they undergo considerable supply-chain disruptions.
  • Among the highest-profile companies to report disruption from the virus are Apple – which has cut its sales expectations for Q2 2020 blaming store and factory closures – and South Korean tech company Samsung, which has been flying and sailing smartphone components into neighbouring Vietnam from China, rather than driving freight across the restricted land border between the countries. 
  • EM investors in the MSCI Emerging Markets ex China Index have been partially protected from the recent sell-off, as the index has been far less volatile than its broad EM counterpart. More on this below.

What’s next?

  • Investor confidence is likely to continue to rise and fall over the coming weeks. Many observers believe that China has learned lessons from previous pandemics and is now much better placed to contain the latest outbreak. Although estimates for Q1 growth are declining, most expect the economy to bounce back from the damage done by the virus, encouraging for the longer-term outlook for multiple sectors even with short-term disruptions. The economic growth forecast for 2020 is estimated to be around 5.5%, down from 5.9% last month.1
  • Global sectors exposed to domestic Chinese growth remain vulnerable. Many businesses have shuttered temporarily for health and safety reasons. Any business involving face-to-face transactions, such as food and drink, and airlines, are particularly vulnerable. Chinese authorities are now considering direct cash infusions or mergers for the hobbled airline industry, as daily nationwide travel remains a fifth of its usual level for this time of the year. Following several high-profile outbreaks aboard cruise ships, companies operating in this industry will also remain under pressure. 
  • Given the high number of companies with parts of their supply chain in China, there are likely to further knock-on effects announced on earnings calls for affected businesses. The tech industry may face short-term disruption, but this should have little lasting impact on tech spending in 2020. The outlook looks worse for the auto sector, which faces challenges from both the decline in domestic demand and China’s position as a key parts supplier to global auto-makers. 
  •  Viral outbreaks develop in unpredictable ways and there may be more bumps in the road over the coming weeks and months. The focus will be on China’s battle to contain Covid-19 and how the economy holds up after the extended shutdowns in the country. Further policy measures aimed at supporting activity are expected over the coming weeks. 

Viral outbreaks: What history tells us

  • After nearly two decades of dealing with mutant viruses (e.g. the 2002/3 SARS scare), Asia has developed the infrastructure and ability needed to better contain the cross-border transmission of viruses. Many observers compare the coronavirus to the 2003 SARS epidemic. Although the Covid-19 virus is genetically similar to SARS, it appears milder in terms of illness and case fatality rate. Another related virus, known as MERS-CoV, has been spreading since 2012 and has led to death in 34% of the 2,499 cases recorded. 
  • By contrast, an estimated 50 million people died in the 1918 Spanish flu pandemic that had a case-fatality rate of less than 5% but infected up to a third of the world’s population. Worst-case scenarios for Covid-19 should use the Asian Flu outbreak of 1957-58 (2 million deaths) or Hong Kong Flu of 1968-69 (1 million deaths) as a base case.
  • SARS had a time-limited negative economic impact. Visitor arrivals and retail sales stabilised within three months of the outbreak being contained.2 The history of SARS and avian flu outbreaks in China suggests that market dips may present an opportunity to buy risk assets at temporarily discounted levels.
  • Research conducted over recent years (e.g. by CDC Atlanta, and the World Bank) suggests that an outbreak like that of 1968-9 would today cause excess deaths in the range of 2 million to 7.4 million, with a GDP loss of $100-200bn for the US and around $550bn for all high-income countries taken together. 
  • Although using history as a template for projections can be useful, China is a much bigger player in the global economy and financial markets now than it was 17 years ago during the SARS outbreak. The Chinese share of global exports has more than tripled since the start of the millennium.3 In 2003, China accounted for 8% of the MSCI Emerging Markets index; today that figure is over 34%.4
  • We believe an allocation to Chinese equities should be managed independently of a broader emerging equities portfolio. Adopting such an approach enables investors to take greater exposure to other markets with improving fundamentals and vary their allocation to China depending on the prevailing market conditions. More volatility for Chinese equities can be expected over the weeks ahead.
  • The volatility profiles of the MSCI EM and MSCI EM ex-China have been very different since the beginning of the outbreak, even though the two indices have fallen by similar amounts. The chart below shows that the volatility of the MSCI EM ex-China has been much lower relative to that of the MSCI EM in recent weeks than it has historically.

MSCI chart

1Source: Bloomberg consensus data as at 19/02/2020

2Source: Asian Development Bank, Economics Paper Working Series, October 2019. https://www.adb.org/sites/default/files/publication/530216/ewp-591-sars-epidemic-2003-economic-costs.pdf

3Source: WTO, World Trade report 2019, November 2019 https://www.wto.org/english/res_e/reser_e/wtr2019_wtr_in_depth.pdf

4Source: MSCI. Data as at 31/01/2020.

Scenarios and related products

Adverse scenario: Cover your bases
 

Source : Lyxor International Asset Management, TER & AuMs correct as at 23/01/2020

Positive scenario: Position for market rebound
 

Source : Lyxor International Asset Management, TER & AuMs correct as at 23/01/2020.

Risk Warning

This document is for the exclusive use of investors acting on their own account and categorised either as “Eligible Counterparties” or “Professional Clients” within the meaning of Markets in Financial Instruments Directive 2014/65/EU. These products comply with the UCITS Directive (2009/65/EC). Société Générale and Lyxor International Asset Management (LIAM) recommend that investors read carefully the “investment risks” section of the product’s documentation (prospectus and KIID). The prospectus and KIID are available free of charge on www.lyxoretf.com, and upon request to client-services-etf@lyxor.com.

Except for the United-Kingdom, where this communication is issued in the UK by Lyxor Asset Management UK LLP, which is authorized and regulated by the Financial Conduct Authority in the UK under Registration Number 435658, this communication is issued by Lyxor International Asset Management (LIAM), a French management company authorized by the Autorité des marchés financiers and placed under the regulations of the UCITS (2014/91/EU) and AIFM (2011/61/EU) Directives. Société Générale is a French credit institution (bank) authorised by the Autorité de contrôle prudentiel et de résolution (the French Prudential Control Authority).

The products mentioned are the object of market-making contracts, the purpose of which is to ensure the liquidity of the products on the London Stock Exchange, assuming normal market conditions and normally functioning computer systems. Units of a specific UCITS ETF managed by an asset manager and purchased on the secondary market cannot usually be sold directly back to the asset manager itself. Investors must buy and sell units on a secondary market with the assistance of an intermediary (e.g. a stockbroker) and may incur fees for doing so. In addition, investors may pay more than the current net asset value when buying units and may receive less than the current net asset value when selling them. Updated composition of the product’s investment portfolio is available on www.lyxoretf.com. In addition, the indicative net asset value is published on the Reuters and Bloomberg pages of the product, and might also be mentioned on the websites of the stock exchanges where the product is listed.

Prior to investing in the product, investors should seek independent financial, tax, accounting and legal advice. It is each investor’s responsibility to ascertain that it is authorised to subscribe, or invest into this product. This document is of a commercial nature and not of a regulatory nature. This material is of a commercial nature and not a regulatory nature. This document does not constitute an offer, or an invitation to make an offer, from Société Générale, Lyxor Asset Management (together with its affiliates, Lyxor AM) or any of their respective subsidiaries to purchase or sell the product referred to herein.

Research disclaimer

Lyxor International Asset Management (“LIAM”) or its employees may have or maintain business relationships with companies covered in its research reports. As a result, investors should be aware that LIAM and its employees may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision. Please see appendix at the end of this report for the analyst(s) certification(s), important disclosures and disclaimers. Alternatively, visit our global research disclosure website www.lyxoretf.com/compliance.

Conflicts of interest 

This research contains the views, opinions and recommendations of Lyxor International Asset Management (“LIAM”) Cross Asset and ETF research analysts and/or strategists. To the extent that this research contains trade ideas based on macro views of economic market conditions or relative value, it may differ from the fundamental Cross Asset and ETF Research opinions and recommendations contained in Cross Asset and ETF Research sector or company research reports and from the views and opinions of other departments of LIAM and its affiliates. Lyxor Cross Asset and ETF research analysts and/or strategists routinely consult with LIAM sales and portfolio management personnel regarding market information including, but not limited to, pricing, spread levels and trading activity of ETFs tracking equity, fixed income and commodity indices. Trading desks may trade, or have traded, as principal on the basis of the research analyst(s) views and reports. Lyxor has mandatory research policies and procedures that are reasonably designed to (i) ensure that purported facts in research reports are based on reliable information and (ii) to prevent improper selective or tiered dissemination of research reports. In addition, research analysts receive compensation based, in part, on the quality and accuracy of their analysis, client feedback, competitive factors and LIAM’s total revenues including revenues from management fees and investment advisory fees and distribution fees.

Connect with us on linkedin